ClinicalTrials.gg
CompletedNCT05949164IPAdUpdated May 21, 2025

The IPAd Study: Exploring the Association Between Insomnia and Positive Airway Pressure Adherence in Children

An observational study in Obstructive Sleep Apnea, Hypoventilation and Central Sleep Apnea, sponsored by The Hospital for Sick Children. Completed at 1 site in Canada. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by The Hospital for Sick Children · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
216
Ages
4 Years to 17 Years
Sex
All
01

Study summary

Sleep-disordered breathing (SDB) is prevalent in children and adolescents and untreated SDB impacts key indicators of physical and psychosocial health. Positive airway pressure (PAP) therapy is highly effective for the treatment of SDB and is associated with favorable clinical outcomes but is limited by poor adherence. Emerging literature in adults suggests that intolerance to PAP therapy may be related to coexisting insomnia. However, the presence of insomnia in children with known SDB as well as its impact on PAP adherence have not been explored. This proposal will explore the association of coexisting insomnia on PAP adherence in children with SDB using a cross-sectional study design. The investigators will assess the association between insomnia and PAP therapy adherence, measured as the mean minutes of nightly PAP usage over 6 months of use on objective downloads.

Read the detailed description

Sleep-disordered breathing (SDB) is prevalent in children and adolescents and untreated SDB impacts key indicators of physical and psychosocial health. Positive airway pressure (PAP) therapy is highly effective for the treatment of SDB and is associated with favorable clinical outcomes but is limited by poor adherence. Emerging literature in adults suggests that intolerance to PAP therapy may be related to coexisting insomnia. This study addresses a critical knowledge gap regarding the association between insomnia and PAP therapy adherence amongst children with SDB. These results will inform future prospective studies on targeted effective interventions to improve PAP adherence in children with SDB.

SDB encompasses a range of breathing disorders during sleep including obstructive sleep apnea (OSA), central sleep apnea (CSA), and hypoventilation. PAP therapy is a common treatment modality for SDB that is often implemented after targeted treatment strategies do not fully cure SDB. PAP therapy, which delivers pressurised air via nasal or oronasal interfaces, effectively distends the upper airway to ameliorate OSA and can assist ventilation with pressure support breaths. PAP is highly efficacious when used on a nightly basis and is typically required for many years into adulthood. The use of PAP has been associated with increased survival and improved health-related quality of life in people with neuromuscular disease. However, SDB remains undertreated or untreated in many children due to poor adherence. A deeper understanding of associations with PAP adherence across the diagnostic spectrum may yield greater benefits for all children on PAP therapy.

Insomnia is highly prevalent in childhood, occurring in up to 37% of children. Insomnia is associated with reduced cognition and academic functioning as well as reduced health-related quality of life, substance use, and increased risk of psychiatric problems. There is emerging evidence that insomnia commonly coexists with OSA in children. A bi-directional causal relationship likely exists whereby OSA is exacerbated by sleep fragmentation, hyper-arousal, and modified sleep architecture associated with insomnia whereas insomnia symptoms are induced by repeated post-obstruction awakenings in OSA. Of importance is that coexisting insomnia and OSA is associated with greater morbidity than either condition alone. To date, there is minimal reported literature on coexisting insomnia with other SDB including CSA and nocturnal hypoventilation. Although similar pathophysiological mechanisms may exist for CSA, there has been little reported in the literature regarding these relationships.

More recently, insomnia has been identified as a risk factor for reduced PAP therapy adherence rates in adult populations due to hypersensitivity to PAP equipment side effects, early discontinuation of therapy, and reduced sleep duration. The impact of insomnia on PAP adherence has never been explored in children. Further, the impact of insomnia on PAP adherence in populations with other SDB diagnoses other than OSA has yet to be explored. Elucidating the impact of coexisting insomnia on PAP adherence may inform future targeted management strategies to improve PAP adherence, such as the addition of cognitive behavioral therapy, and may lead to improved outcomes in children with SDB.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Hypoventilation
  • Central Sleep Apnea
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's enrollment of 216 is above the median of 105 across 666 observational studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 578 studies on the registry; 83 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children and adolescents established on PAP therapy

Eligibility criteria

Participant Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Children aged 4-17 years old
  2. Prescribed PAP therapy for at least 6 months

Participant Exclusion Criteria

An individual or caregiver who meets one or more of the following criteria will be excluded from participation in this study:

  1. Limited knowledge and proficiency in English to complete the study as judged by the clinical team.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
216 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1: Children able to answer questionnaires independently

    Children who are deemed by a healthcare professional to be able to answer questionnaires independently (group 1) will be asked to complete self-reported questionnaires. Caregivers will also be asked to complete proxy-reported questionnaires.

    Behavioral: Insomnia

  • Group 2: Children unable to answer questionnaires

    The caregivers of children who are deemed by a healthcare professional to be unable to answer questionnaires (group 2) will be invited to complete proxy-reported questionnaires only. There are no self-reported questionnaires for this group.

    Behavioral: Insomnia

Interventions

  • BehavioralInsomnia

    The primary exposure is insomnia

06

What researchers measure

Primary outcomes

  1. PAP therapy adherence

    PAP therapy adherence measured as the mean minutes of nightly PAP usage over 6 months

    Time frame: 6 months

Secondary outcomes

  1. PAP therapy adherence

    PAP therapy adherence expressed as a percentage of total sleep time

    Time frame: 6 months

  2. PAP therapy adherence

    PAP therapy adherence measured as the mean minutes of nightly PAP usage over 3 months

    Time frame: 3 months

  3. PAP therapy adherence

    PAP therapy adherence expressed as a percentage of total sleep time

    Time frame: 3 months

  4. PAP therapy adherence

    PAP therapy adherence measured as the mean minutes of nightly PAP usage over 2 weeks

    Time frame: 2 weeks

  5. PAP therapy adherence

    PAP therapy adherence expressed as a percentage of total sleep time

    Time frame: 2 weeks

  6. PAP therapy adherence

    PAP therapy adherence expressed as a dichotomous outcome (PAP usage for at least 4 hours per night for 70% of nights)

    Time frame: 3 months

  7. PAP therapy adherence

    PAP therapy adherence expressed as a dichotomous outcome (PAP usage for at least 6 hours per night for 70% of nights)

    Time frame: 3 months

  8. PAP therapy adherence

    PAP therapy adherence expressed as a dichotomous outcome (PAP usage for at least 4 hours per night for 70% of nights)

    Time frame: 6 months

  9. PAP therapy adherence

    PAP therapy adherence expressed as a dichotomous outcome (PAP usage for at least 6 hours per night for 70% of nights)

    Time frame: 6 months

  10. Physical Well-being (percentage rank)

    The Physical Well-being Scale from the KIDSCREEN-27 questionnaire will be used. The percentage rank range is 0-100, with lower scores indicating lower physical well-being.

    Time frame: 1 week

  11. Psychological Well-being (percentage rank)

    The Psychological Well-being Scale from the KIDSCREEN-27 questionnaire will be used. The percentage rank range is 0-100, with lower scores indicating a "dissatisfaction with life".

    Time frame: 1 week

  12. Autonomy and Parent Relation (percentage rank)

    The Autonomy and Parent Relation Well-being Scale from the KIDSCREEN-27 questionnaire will be used. The percentage rank range is 0-100, with lower scores indicating lower autonomy.

    Time frame: 1 week

  13. Self-Perception (percentage rank)

    The Self-Perception Scale from the KIDSCREEN-27 questionnaire will be used. The percentage rank range is 0-100, with lower scores indicating lower self-perception.

    Time frame: 1 week

  14. Social Support and Peers (percentage rank)

    The Social Support and Peers Scale from the KIDSCREEN-27 questionnaire will be used. The percentage rank range is 0-100, with lower scores indicating lower social support.

    Time frame: 1 week

  15. Daytime Sleepiness

    The Epworth Sleepiness Scale is scored from 0-24, with higher scores indicating greater sleepiness.

    Time frame: 1 month

  16. Depressive Symptoms (T-score)

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Item Bank v2.0 - Depressive Symptoms Questionnaire generates a T-score. Higher scores indicate increased depressive symptoms (patient-reported questionnaire range 35.2-82.4).

    Time frame: 7 days

  17. Depressive Symptoms (T-score)

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Parent Proxy Bank v2.0 - Depressive Symptoms Questionnaire generates a T-score. Higher scores indicate increased depressive symptoms (proxy-reported questionnaire range 36.2-84.7).

    Time frame: 7 days

  18. Anxiety Symptoms (T-score)

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Bank v2.0 - Anxiety Questionnaire generates a T-score. Higher scores indicate increased anxiety symptoms (patient-reported questionnaire range 33.5-83.3).

    Time frame: 7 days

  19. Anxiety Symptoms (T-score)

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Parent Proxy Bank v2.0 - Anxiety Questionnaire generates a T-score. Higher scores indicate increased anxiety symptoms (proxy-reported questionnaire range 34.6-86.4).

    Time frame: 7 days

  20. Chronotype

    Measured with the Children's Chronotype Questionnaire. The chronotype categorizations including morningness, eveningness, and neither.

    Time frame: 4 week

  21. Chronotype

    Measured with the Reduced Morningness-Eveningness questionnaire. The chronotype categorizations including morningness, eveningness, and neither.

    Time frame: 4 week

  22. Chronotype

    Measured with the Munich Chronotype Questionnaire for Children and Adolescents. The chronotype categorizations including morningness, eveningness, and neither.

    Time frame: 4 week

  23. Mid-Sleep Point

    Measured with the Munich Chronotype Questionnaire for Children and Adolescents

    Time frame: 4 week

  24. Mid-Sleep Point

    Measured with the Children's Chronotype Questionnaire

    Time frame: 4 week

  25. Sleep Hygiene (total score)

    The Adolescent Sleep Hygiene Scale total score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  26. Sleep Hygiene (Physiological Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  27. Sleep Hygiene (Behavioral Arousal Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  28. Sleep Hygiene (Cognitive/Emotional Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  29. Sleep Hygiene (Sleep Environment Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  30. Sleep Hygiene (Sleep Stability Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  31. Sleep Hygiene (Daytime Sleep Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  32. Sleep Hygiene (Substances Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  33. Sleep Hygiene (Bedtime Routine Factor)

    Subscale from the Adolescent Sleep Hygiene Scale total score. The score ranges from 1-6. Higher scores indicate better success with sleep hygiene.

    Time frame: 1 month

  34. Adherence Barriers to CPAP

    The score range for the Adherence Barriers to CPAP Questionnaire is 31-155. Higher scores indicate more barriers.

    Time frame: 2 weeks

  35. Total Difficulties Score

    The Strengths and Difficulties Questionnaire generates a total difficulties score ranging from 0-40, with higher scores indicating greater behavioral difficulty.

    Time frame: 6 months

  36. Emotional Problems Score

    The Strengths and Difficulties Questionnaire generates an emotional problems score ranging from 0-10, with higher scores indicating greater difficulty.

    Time frame: 6 months

  37. Conduct Problems Score

    The Strengths and Difficulties Questionnaire generates a conduct problems score ranging from 0-10, with higher scores indicating greater difficulty.

    Time frame: 6 months

  38. Hyperactivity Score

    The Strengths and Difficulties Questionnaire generates a hyperactivity score ranging from 0-10, with higher scores indicating greater difficulty.

    Time frame: 6 months

  39. Peer Problems Score

    The Strengths and Difficulties Questionnaire generates a peer problems score ranging from 0-10, with higher scores indicating greater difficulty.

    Time frame: 6 months

  40. Prosocial Score

    The Strengths and Difficulties Questionnaire generates a prosocial score ranging from 0-10, with higher scores indicating greater prosocial behavior.

    Time frame: 6 months

07

Study locations

1 site
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in May 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2023
First posted
Jul 17, 2023
StartActual
May 16, 2023
Primary completionActual
May 1, 2024
CompletionActual
May 1, 2025
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949164
Responsible party
Indra Narang (Professor, The Hospital for Sick Children) — Principal investigator
First posted
Jul 17, 2023
Start date
May 16, 2023
Primary completion
May 1, 2024
Completion
May 1, 2025
Last update
May 21, 2025

Study contacts

Indra Narang, MD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion